LENA Molecular Diagnostic (DX) Platform was created to offer practitioners access to the largest variety of Leukemia related diagnostic tests for early detection then for guidance in treatments. All the LENA Tests are new generation DNA Sequencing tests and offer high quality tests with the highest accuracy and sensitivity available on the market.
Alercell R&D team is constantly working to add new tests to cover all the aspects of Leukemia testing to provide practitioners with every single test available.
Alercell is making sure that all the tests are offered at very competitive pricing. Alercell strong belief is that giving access to many patients, hospitals and cancer centers to quality testing at a limited price will increase the quantity of tests, thus will permit early detection and fast treatment of Leukemia. Practitioners should take treatment decisions based on medical data not on costs consideration.
BCR-ABL1 refers to a gene sequence found in an abnormal chromosome 22 of some people with certain forms of leukemia.
Unlike most cancers, the cause of chronic myelogenous leukemia (CML) and some other leukemias can be traced to a single, specific genetic abnormality in one chromosome.
The presence of the gene sequence known as BCR-ABL1 confirms the diagnosis of CML and a form of acute lymphoblastic lymphoma (ALL), specifically a type of B-lymphoblastic leukemia/lymphoma. In very rare cases, the abnormal chromosome is linked to cases of acute myeloid leukemia and T-lymphoblastic leukemia/lymphoma.
LENA BCR-ABL1 Genotyping Kit is a qualitative in vitro diagnostic test for differentiating of BCR-ABL1 p210, BCR-ABL1 p190, BCR-ABL1 p230 three splice variants with leukemia. The kit detects RNA transcripts of fusion genes extracted from human bone marrow or whole blood samples with BCR-ABL1. The results obtained from the kit provides more information of BCR-ABL1 to professionals for comprehensive consideration associated with patient condition, drug indication, therapeutic response and other detection findings.
BCR-ABL1 P190 Kit is intended to quantify the BCR-ABL1 P190 transcripts in human bone marrow or whole blood samples of leukemia patients. The results obtained from the kit provides information about efficiency of treatment or Minimal Residual Disease (MRD) in patients.
BCR-ABL1 P210 Kit is intended to quantify the BCR-ABL1 P210 transcripts in human bone marrow or whole blood samples of leukemia patients. The results obtained from the kit provides information about efficiency of treatment or Minimal Residual Disease (MRD) in patients.
The results obtained from the kits provides more information to professionals for comprehensive consideration associated with patient condition, drug indication, therapeutic response and other detection findings. The results obtained from the kits provide information about efficiency of treatment or Minimal Residual Disease (MRD) in patients.
PML-RARΑ L Detection Kit is intended to quantify the PML-RARα L transcripts in human bone marrow or whole blood samples of leukemia patients.
PML-RARΑ S Detection Kit is intended to quantify the PML-RARα S transcripts in human bone marrow or whole blood samples of leukemia patients.
PML-RARΑ V Detection Kit is intended to quantify the PML-RARα V transcripts in human bone marrow or whole blood samples of leukemia patients.
PML-RARα Genotyping Kit is a qualitative in vitro diagnostic test for differentiating of PML-RARα L, PML-RARα S and PML-RARα V three splice variants with leukemia. The kit detects RNA transcripts of fusion genes extracted from human bone marrow or whole blood samples with PML-RARα.
WT1 Detection Kit is intended to quantify the WT1 transcripts in human bone marrow or whole blood samples of leukemia patients.
CBFΒ-MYH11 Detection Kit is intended to quantify the CBFβ-MYH11 transcripts in human bone marrow or whole blood samples of leukemia patients.
The results obtained from the kit provides information about efficiency of treatment or Minimal Residual Disease (MRD) in patients.
